SCHEMBL6255366

SCHEMBL6255366

CC(C)(C)C(Cc1cccc(-c2ccc(C=O)cc2)c1)NC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME P08473 2/20 0.42
ACE P12821 2/20 0.42
ACE2 Q9BYF1 2/20 0.42
CPA1 P15085 1/20 0.42
SHMT1 P34896 1/20 0.42
SHMT2 P34897 1/20 0.42
CTSB P07858 2/20 0.42
CTSS P25774 2/20 0.42
CTSK P43235 2/20 0.42
MMP2 P08253 2/20 0.42
MMP3 P08254 2/20 0.42
CTSL P07711 1/20 0.42
PTGS2 P35354 2/20 0.41
DRD1 P21728 1/20 0.40
ADAMTS4 O75173 2/20 0.40
TRIM24 O15164 1/20 0.40
TRIM33 Q9UPN9 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
GRIA2 P42262 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6032488 0.86 GRIA2 (0.48) MMEACEACE2CPA1SHMT1
SCHEMBL1936821 0.83 EPHX2 (0.43) MMEACEACE2CPA1MMP2
SCHEMBL1750860 0.81 HPGDS (0.42) MMEACEACE2CPA1CTSB
SCHEMBL2177211 0.77 DRD1 (0.43) SHMT1SHMT2CTSSCTSKMMP2
SCHEMBL3974459 0.76 CTSB (0.49) CTSBCTSSCTSKCTSLPTGES
SCHEMBL2174522 0.74 AOC3 (0.55) DRD1TRIM24TRIM33BCL2
SCHEMBL2237120 0.74 MMP2 (0.50) MMP2MMP3
SCHEMBL1124875 0.72 GRIN2D (0.55) PTGS2DRD1TRIM24TRIM33BCL2
SCHEMBL3948564 0.72 PLAAT3 (0.50) MMP2DRD1TRIM24TRIM33MMP1
SCHEMBL2177213 0.72 MEN1 (0.47) DRD1TRIM24TRIM33PTGESBCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567509-A2 BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2005-08-31 EP disclosed
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
WO-2004048351-A2 BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-06-10 WO disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD MME 4767/4885ACE 3269/4885ACE2 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.